ORGANIC COMPOUNDS

Acta Cryst. (1998). C54, 1106-1107

(2R,3S)-3-Phenyl-2-[(2S,4S)-4-phenyl-3-tosyl-1,3-oxazolidin-2-yl]cyclopentanone

BERND BERGER AND MICHAEL BOLTE

Institut für Organische Chemie, J. W. Goethe-Universität Frankfurt, Marie-Curie-Str. 11, 60439 Frankfurt/Main, Germany. E-mail: bolte@chemie.uni-frankfurt.de

(Received 4 December 1997; accepted 4 February 1998)

Abstract

The stereochemical parameters of the title compound, $C_{27}H_{27}NO_4S$, are in good agreement with other arylsulfonyloxazolidines. Whereas the oxazolidine ring displays a twist conformation, the cyclopentanone ring has an envelope conformation.

Comment

The acid-catalysed condensation of 2-(*N*-tosyl)-1-alkanoles with aldehydes usually produces the thermodynamically more stable 2,4-cis-substituted 1,3-ox-azolidines (Hoppe et al., 1991). From the reaction of (*S*)-*N*-tosylphenylglycinol and 2-(hydroxymethylene)-cyclopentanone, we isolated traces of a by-product which turned out to have the *trans* configuration (Bolte & Berger, 1996). However, the reaction of (*S*)-*N*-tosylphenylglycinol and 2-(hydroxymethylene)-4-phenylcyclopentanone afforded the expected *cis* product, (I). The oxazolidine ring adopts a twist conformation $[q_2 = 0.275 (3) \text{ Å}$ and $\varphi_2 = 121.1 (6)^{\circ}$; Cremer & Pople,

1975], with C4 and C5 deviating by -0.277 (7) and 0.185 (8) Å, respectively, from the plane of the remaining three atoms. The cyclopentanone ring exhibits an envelope conformation $[q_2 = 0.404$ (3) Å and $\varphi_2 = 322.3$ (4)°], with C25 deviating by 0.621 (4) Å from the plane of the remaining four atoms. The geometric parameters of the sulfonamide moiety agree well with those found by Herbst-Irmer (1990).




Fig. 1. Perspective view of the title compound with the atomnumbering scheme; displacement ellipsoids are at the 50% probability level.

Experimental

Single crystals of the title compound were obtained from a diethyl ether solution by slow evaporation of the solvent.

Crystal data

 $C_{27}H_{27}NO_4S$ Cu $K\alpha$ radiation $M_r = 461.56$ $\lambda = 1.5418 \text{ Å}$ Monoclinic Cell parameters from 25 $P2_1$ reflections a = 9.783(2) Å $\theta = 30-40^{\circ}$ b = 11.910(1) Å $\mu = 1.472 \text{ mm}^{-1}$ c = 10.395(2) ÅT = 293(2) K $\beta = 99.11(1)^{\circ}$ Transparent block $V = 1195.9 (4) \text{ Å}^3$ $0.40\,\times\,0.40\,\times\,0.20~mm$ Colourless $D_x = 1.282 \text{ Mg m}^{-3}$

Data collection

Enraf-Nonius CAD-4 fourcircle diffractometer ω scans Absorption correction: empirical, measuring nine ψ scans (North *et al.*, 1968) $T_{\text{min}} = 0.702$, $T_{\text{max}} = 0.745$ 3009 measured reflections 2837 independent reflections

Refinement

Refinement on F^2 $R[F^2 > 2\sigma(F^2)] = 0.032$ $wR(F^2) = 0.086$ S = 1.071 2813 reflections with $I > 2\sigma(I)$ $R_{\text{int}} = 0.031$ $\theta_{\text{max}} = 59.90^{\circ}$ $h = -10 \rightarrow 10$ $k = -13 \rightarrow 6$ $l = -11 \rightarrow 0$ 3 standard reflections frequency: 92 min intensity decay: 1.0%

Extinction correction: SHELXL96
Extinction coefficient: 0.0102 (6)

2837 reflections 300 parameters H atoms: see below $w = 1/[\sigma^2(F_o^2) + (0.0557P)^2 + 0.2002P]$ where $P = (F_o^2 + 2F_c^2)/3$ $(\Delta/\sigma)_{\text{max}} = 0.001$ $\Delta\rho_{\text{max}} = 0.319 \text{ e Å}^{-3}$ $\Delta\rho_{\text{min}} = -0.224 \text{ e Å}^{-3}$

Scattering factors from
International Tables for
Crystallography (Vol. C)
Absolute structure: Flack
(1983)
Flack parameter =
-0.004 (17)

 Sheldrick, G. M. (1991). SHELXTL-Plus. Release 4.1. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
 Sheldrick, G. M. (1996). SHELXL96. Program for the Refinement of Crystal Structures. University of Göttingen, Germany.

Table 1. Selected geometric parameters (Å, °)

	-	-	
O1—C5 O1—C2 C2—N3 N3—C4 N3—S3	1.394 (4) 1.396 (3) 1.497 (3) 1.491 (3) 1.6441 (19)	C4—C5 S3—O32 S3—O31 S3—C31	1.525 (3) 1.4264 (19) 1.427 (2) 1.762 (3)
C5—O1—C2 O1—C2—N3 C4—N3—C2 C4—N3—S3 C2—N3—S3 N3—C4—C5 O1—C5—C4	110.7 (2) 106.0 (2) 107.67 (18) 116.96 (16) 116.36 (16) 100.2 (2) 107.1 (2)	O32—S3—O31 O32—S3—N3 O31—S3—N3 O32—S3—C31 O31—S3—C31 N3—S3—C31	120.33 (12) 106.30 (10) 106.04 (12) 107.92 (12) 107.91 (12) 107.77 (10)
C5—O1—C2—N3 O1—C2—N3—C4 C2—N3—C4—C5 C2—O1—C5—C4 N3—C4—C5—O1	8.2 (3) 11.2 (3) -23.7 (3) -24.1 (4) 28.9 (3)	C25—C21—C22—C23 C21—C22—C23—C24 C2—C21—C25—C24 C22—C21—C25—C24 C23—C24—C25—C21	165.9 (2)

The structure was solved by extracting the position of the S atom from a sharpened Patterson list and extending the structure with a tangent expansion using SHELXS96 (Sheldrick, 1990), and then refined with SHELXL96 (Sheldrick, 1996) by full-matrix least-squares methods. All H atoms were located by difference Fourier syntheses and refined with fixed individual displacement parameters $[U(H) = 1.5U_{eq}(C_{methyl})]$ or $U(H) = 1.2U_{eq}(C)]$, using a riding model with C—H(tertiary) = 0.98, C—H(secondary) = 0.97, C—H(methyl) = 0.96 or C—H(aromatic) = 0.93 Å.

Data collection: *SDP* (Enraf-Nonius, 1985). Cell refinement: *SDP*. Data reduction: *SDP*. Molecular graphics: *XP* in *SHELXTL-Plus* (Sheldrick, 1991).

We thank Professor Dr D. Hoppe (University of Münster, Germany) for providing us with the sample of the title compound.

Supplementary data for this paper are available from the IUCr electronic archives (Reference: JZ1271). Services for accessing these data are described at the back of the journal.

References

Bolte, M. & Berger, B. (1996). *Acta Cryst.* C**52**, 1987–1989. Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **89**, 6193–6200. Enraf–Nonius (1985). *SDP Structure Determination Package*. Enraf–Nonius, Delft, The Netherlands.

Flack, H. D. (1983). Acta Cryst. A39, 876-881.

Herbst-Irmer, R. (1990). PhD thesis, University of Göttingen, Germany.

Hoppe, I., Hoffmann, H., Gärtner, I., Krettek, T. & Hoppe, D. (1991). Synthesis, pp. 1157-1162.

North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). Acta Cryst. A24, 351–359.

Sheldrick, G. M. (1990). Acta Cryst. A46, 467-473.

Acta Cryst. (1998). C54, 1107-1109

2,3,4,5-Tetrahydrocyclohepta[*b*]pyrido-[2,1-*a*]benzimidazole-7-carbonitrile

GALAL E. H. ELGEMEIE, a NAHED M. FATHY, b HENNING HOPF, c INA DIX c AND PETER G. JONES d*

^aChemistry Department, Faculty of Science, Helwan University, Helwan, Cairo, Egypt, ^bPhotochemistry Laboratory, National Research Centre, Cairo, Egypt, ^cInstitut für Organische Chemie, Technische Universität Braunschweig, Postfach 3329, 38023 Braunschweig, Germany, and ^dInstitut für Anorganische und Analytische Chemie, Technische Universität Braunschweig, Postfach 3329, 38023 Braunschweig, Germany. E-mail: jones@xray36.anchem.nat.tu-bs.de

(Received 27 January 1998; accepted 24 February 1998)

Abstract

The title compound, $C_{17}H_{15}N_3$, is a tetracyclic system in which the atoms of the three unsaturated rings are coplanar to within 0.026 Å. The molecules are stacked in pairs about inversion centres, with the shortest $C \cdot \cdot \cdot C$ separation being 3.386 (4) Å.

Comment

The imidazole and imidazo[1,2-a]pyridine ring systems are components of heterocycles that have shown antitumor activity (Elgemeie et al., 1996). Our interest in the development of novel non-classical antimetabolites directed us towards the synthesis of new tetracyclic antimetabolites involving the imidazo[1,2-a]pyridine system (Elgemeie & Hussain, 1994; Elgemeie et al., 1994). A single-step synthesis of the title derivative (6) was anticipated via the cyclocondensation of 2-cyanobenzimidazole and the sodium salt of 2-(hydroxymethylene)-1-cycloheptanone. However, this reaction could give three other possible regioisomers [structures (3)–(5)]. The direction of ring closure in such cyclocondensations is difficult to predict, and spectroscopic data cannot differentiate between these structures. In order to establish unambiguously the structure of the product, the crystal structure was determined.